drugset / Trial / NCT00656461
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label study to determine the highest dose of MKC-1 that may be administered daily on a continuous basis for patients with advanced or refractory solid tumors.
Timeline
- Start
- 2008-03
- Primary completion
- 2009-07
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MKC-1 | Small molecule | 30 mg | — |
| Subject | MKC-1 | Small molecule | 100 mg | — |